NASDAQ:RVPH - Reviva Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.00
  • Forecasted Upside: 733.33 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$1.20
▲ +0.1 (9.09%)

This chart shows the closing price for RVPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Reviva Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVPH

Analyst Price Target is $10.00
▲ +733.33% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Reviva Pharmaceuticals in the last 3 months. The average price target is $10.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 733.33% upside from the last price of $1.20.

This chart shows the closing price for RVPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Reviva Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/24/2022HC WainwrightInitiated CoverageBuy$10.00High
7/26/2021Maxim GroupInitiated CoverageBuy$10.00High
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/6/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/5/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/4/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/6/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
4/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
6/4/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/4/2022

Current Sentiment

  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Reviva Pharmaceuticals logo
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP5063, which is in Phase III clinical trials for the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company is headquartered in Cupertino, California.
Read More

Today's Range

Now: $1.20
Low: $1.17
High: $1.26

50 Day Range

MA: $1.56
Low: $1.03
High: $2.12

52 Week Range

Now: $1.20
Low: $1.00
High: $4.79

Volume

3,667 shs

Average Volume

340,167 shs

Market Capitalization

$18.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of Reviva Pharmaceuticals?

The following sell-side analysts have issued reports on Reviva Pharmaceuticals in the last year: HC Wainwright, and Maxim Group.
View the latest analyst ratings for RVPH.

What is the current price target for Reviva Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Reviva Pharmaceuticals in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 733.3%.
View the latest price targets for RVPH.

What is the current consensus analyst rating for Reviva Pharmaceuticals?

Reviva Pharmaceuticals currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RVPH will outperform the market and that investors should add to their positions of Reviva Pharmaceuticals.
View the latest ratings for RVPH.

How do I contact Reviva Pharmaceuticals' investor relations team?

Reviva Pharmaceuticals' physical mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The company's listed phone number is (408) 501-8881 and its investor relations email address is ir.revivapharma.com. The official website for Reviva Pharmaceuticals is www.revivapharma.com. Learn More about contacing Reviva Pharmaceuticals investor relations.